Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-erbB-4
Authors:
Open Access
- 1 April 2003
- journal article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 56 (4) , 300-304
Abstract
Background: There is a clear need to define biological markers that will predict the response to treatment in breast cancer, and several recent studies suggest that the expression of type 1 growth factor receptors may prove important in this regard. The type 1 growth factor receptors are a family of transmembrane receptors comprising epidermal growth factor receptor (EGFR), c-erbB-2, c-erbB-3, and c-erbB-4. Both EGFR and c-erbB-2 are associated with poor prognosis in certain tumours. Aims: There is very little information concerning expression patterns of the full range of type 1 growth factor receptors, especially with respect to c-erbB-3 and c-erbB-4. Therefore, this study was designed to compare the expression of each, and to assess whether expression of any of the factors was related to patient survival in a clinical series. Methods: Type 1 growth factor receptor expression was investigated by means of immunohistochemistry in a series of node positive patients with breast cancer (n = 66), and statistical analysis was carried out to determine associations between variables and survival analysis for each variable. Results: There were several correlations between variables, and overexpression of EGFR, c-erbB-2, and c-erbB-4 was found to be associated with adverse clinical outcome, although the results were significant only for c-erbB-4 (p = 0.002). Conclusion: Although patient numbers are small, this is the first report describing c-erbB-4 as an adverse prognostic marker. These findings are in contrast to previous investigations and may relate to the fact that the patients studied all had advanced stage disease and had undergone similar chemotherapy regimens in the context of a clinical trial.Keywords
This publication has 22 references indexed in Scilit:
- The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.2001
- STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsOncogene, 2001
- Correlation between c-erbB-4 receptor expression and response to gemcitabine–cisplatin chemotherapy in non-small-cell lung cancerAnnals of Oncology, 2001
- Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene AmplificationJournal of Clinical Oncology, 2001
- Estrogen receptor-α and C-ERBB-4 expression in breast carcinomasVirchows Archiv, 2001
- Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay.2000
- Nuclear expression of the c-erbB-4/HER-4 growth factor receptor in invasive breast cancers.2000
- Amplification and Deletion of Topoisomerase IIα Associate with ErbB-2 Amplification and Affect Sensitivity to Topoisomerase II Inhibitor Doxorubicin in Breast CancerThe American Journal of Pathology, 2000
- Perceptions of Herceptin®: A Monoclonal Antibody for the Treatment of Breast CancerCancer Biotherapy and Radiopharmaceuticals, 1999
- The type 1 growth factor receptor family: new ligands and receptors and their role in breast cancerBreast Cancer Research and Treatment, 1998